In contrast, a chemotherapy-free regimen is being evaluated by SKYSCRAPER-05 (NCT03563716), a global neoadjuvant phase II trial of the anti-PD-L1 antibody atezolizumab plus the anti-TIGIT antibody tiragolumab with or without platinum-based chemotherapy in patients with locally advanced resectable stage II‒IIIB NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.